MiR-135-5p promotes osteoblast differentiation by targeting HIF1AN in MC3T3-E1 cells. 2019

Nuo Yin, and Longzhang Zhu, and Liang Ding, and Junjie Yuan, and Li Du, and Mingmang Pan, and Feng Xue, and Haijun Xiao
Department of Orthopaedics, Shanghai Fengxian District Central Hospital, No. 6600, Nanfeng Highway, Shanghai, 201499 China.

BACKGROUND MicroRNAs (miRNAs or miRs) serve crucial roles in the progression of osteoporosis. This study investigated the role and specific molecular mechanism of miR-135-5p in regulating osteoblast differentiation and calcification. METHODS Bone morphogenetic protein 2 (BMP2) was employed to interfere with the differentiation of MC3T3-E1. Then, miR-135-5p mimic or miR-135-5p inhibitor was transfected into MC3T3-E1, and quantitative RT-PCR was used to measure the expression of miR-135-5p. The expressions of runt-related transcription factor 2 (Runx2), osterix (OSX), osteopontin (OPN), and osteocalcin (OCN) were determined using western blot. Alkaline phosphatase (ALP) activity was measured using an appropriate kit assay. Calcium nodule staining was evaluated with alizarin red staining. A luciferase reporter assay was used to verify the target of miR-135-5p. Hypoxia-inducible factor 1 α inhibitor (HIF1AN) overexpression was applied to investigate its own role in the mechanism and a miR-135-5p rescue experiment was also performed. RESULTS Overexpression of miR-135-5p promoted osteogenic differentiation and calcification, as shown by the increase in ALP activity, calcification and osteogenic marker levels, including Runx2, OSX, OPN and OCN. Knockdown of miR-135-5p yielded the opposite results. HIF1AN was confirmed as a direct target of miR-135-5p. HIF1AN overexpression inhibited osteogenic differentiation and calcification while miR-135-5p reversed these effects. CONCLUSIONS These results indicate that miR-135-5p might have a therapeutic application related to its promotion of bone formation through the targeting of HIF1AN.

UI MeSH Term Description Entries
D010006 Osteoblasts Bone-forming cells which secrete an EXTRACELLULAR MATRIX. HYDROXYAPATITE crystals are then deposited into the matrix to form bone. Osteoblast
D010012 Osteogenesis The process of bone formation. Histogenesis of bone including ossification. Bone Formation,Ossification, Physiologic,Endochondral Ossification,Ossification,Ossification, Physiological,Osteoclastogenesis,Physiologic Ossification,Endochondral Ossifications,Ossification, Endochondral,Ossifications,Ossifications, Endochondral,Osteoclastogeneses,Physiological Ossification
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006899 Mixed Function Oxygenases Widely distributed enzymes that carry out oxidation-reduction reactions in which one atom of the oxygen molecule is incorporated into the organic substrate; the other oxygen atom is reduced and combined with hydrogen ions to form water. They are also known as monooxygenases or hydroxylases. These reactions require two substrates as reductants for each of the two oxygen atoms. There are different classes of monooxygenases depending on the type of hydrogen-providing cosubstrate (COENZYMES) required in the mixed-function oxidation. Hydroxylase,Hydroxylases,Mixed Function Oxidase,Mixed Function Oxygenase,Monooxygenase,Monooxygenases,Mixed Function Oxidases,Function Oxidase, Mixed,Function Oxygenase, Mixed,Oxidase, Mixed Function,Oxidases, Mixed Function,Oxygenase, Mixed Function,Oxygenases, Mixed Function
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018507 Gene Expression Regulation, Developmental Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action during the developmental stages of an organism. Developmental Gene Expression Regulation,Embryologic Gene Expression Regulation,Gene Expression Regulation, Embryologic,Regulation of Gene Expression, Developmental,Regulation of Gene Expression, Embryologic,Regulation, Gene Expression, Developmental,Regulation, Gene Expression, Embryologic
D035683 MicroRNAs Small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length generated from single-stranded microRNA gene transcripts by the same RIBONUCLEASE III, Dicer, that produces small interfering RNAs (RNA, SMALL INTERFERING). They become part of the RNA-INDUCED SILENCING COMPLEX and repress the translation (TRANSLATION, GENETIC) of target RNA by binding to homologous 3'UTR region as an imperfect match. The small temporal RNAs (stRNAs), let-7 and lin-4, from C. elegans, are the first 2 miRNAs discovered, and are from a class of miRNAs involved in developmental timing. RNA, Small Temporal,Small Temporal RNA,miRNA,stRNA,Micro RNA,MicroRNA,Primary MicroRNA,Primary miRNA,miRNAs,pre-miRNA,pri-miRNA,MicroRNA, Primary,RNA, Micro,Temporal RNA, Small,miRNA, Primary,pre miRNA,pri miRNA

Related Publications

Nuo Yin, and Longzhang Zhu, and Liang Ding, and Junjie Yuan, and Li Du, and Mingmang Pan, and Feng Xue, and Haijun Xiao
March 2018, Molecular medicine reports,
Nuo Yin, and Longzhang Zhu, and Liang Ding, and Junjie Yuan, and Li Du, and Mingmang Pan, and Feng Xue, and Haijun Xiao
July 2019, Experimental and therapeutic medicine,
Nuo Yin, and Longzhang Zhu, and Liang Ding, and Junjie Yuan, and Li Du, and Mingmang Pan, and Feng Xue, and Haijun Xiao
March 2019, International journal of molecular medicine,
Nuo Yin, and Longzhang Zhu, and Liang Ding, and Junjie Yuan, and Li Du, and Mingmang Pan, and Feng Xue, and Haijun Xiao
January 2001, Biochemical and biophysical research communications,
Nuo Yin, and Longzhang Zhu, and Liang Ding, and Junjie Yuan, and Li Du, and Mingmang Pan, and Feng Xue, and Haijun Xiao
January 2018, Experimental cell research,
Nuo Yin, and Longzhang Zhu, and Liang Ding, and Junjie Yuan, and Li Du, and Mingmang Pan, and Feng Xue, and Haijun Xiao
June 2020, Mechanisms of development,
Nuo Yin, and Longzhang Zhu, and Liang Ding, and Junjie Yuan, and Li Du, and Mingmang Pan, and Feng Xue, and Haijun Xiao
December 2016, Molecules (Basel, Switzerland),
Nuo Yin, and Longzhang Zhu, and Liang Ding, and Junjie Yuan, and Li Du, and Mingmang Pan, and Feng Xue, and Haijun Xiao
June 2004, Journal of cellular biochemistry,
Nuo Yin, and Longzhang Zhu, and Liang Ding, and Junjie Yuan, and Li Du, and Mingmang Pan, and Feng Xue, and Haijun Xiao
February 2023, Shanghai kou qiang yi xue = Shanghai journal of stomatology,
Nuo Yin, and Longzhang Zhu, and Liang Ding, and Junjie Yuan, and Li Du, and Mingmang Pan, and Feng Xue, and Haijun Xiao
February 2019, European journal of pharmacology,
Copied contents to your clipboard!